Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov page’s footer revision changes from v3.8.0 to v3.8.1; the study content remains unchanged.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial record for androgen deprivation therapy combined with pembrolizumab is displayed, with details about the study design, participant eligibility, participating locations, and measured outcomes.SummaryDifference51%

- Check21 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 error.SummaryDifference0.3%

- Check28 days agoChange DetectedA dismissible NIH banner announces website updates and a transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov error page displays an updated site revision identifier, from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check42 days agoChange DetectedThe ClinicalTrials.gov error page’s footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.